Halozyme Therapeutics (HALO) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Halozyme Therapeutics (HALO) PT Cut to $15 at Piper Jaffray
November 11, 2014 7:35 AM ESTPiper Jaffray analyst Charles Duncan lowered his price target on Halozyme Therapeutics (NASDAQ: HALO) to $15.00 (from $20.00) following Q3 results but retained an Overweight rating.
Duncan commented, "Halozyme reported 3Q earnings yesterday, ending the quarter with $135M, which we view as still potentially... More
